oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Microscopic colitis: current status, present and future challenges statements of the European microscopic colitis group
Faculty of Health Science, Linköping University, Linköping, Sweden.
Department of Pathology, University Hospital, Dresden, Germany.
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Diagnostic Center, Division of Gastroenterology, Regional Hospital, Silkeborg, Denmark.
Show others and affiliations
2012 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 6, no 9, p. 932-945Article in journal (Refereed) Published
Abstract [en]

Microscopic colitis (MC) is an inflammatory bowel disease presenting with chronic, non-bloody watery diarrhoea and few or no endoscopic abnormalities. The histological examination reveals mainly two subtypes of MC, lymphocytic or collagenous colitis. Despite the fact that the incidence in MC has been rising over the last decades, research has been sparse and our knowledge about MC remains limited. Specialists in the field have initiated the European Microscopic Colitis Group (EMCG) with the primary goal to create awareness on MC. The EMCG is furthermore a forum with the intention to promote clinical and basic research. In this article statements and comments are given that all members of the EMCG have considered being of importance for a better understanding of MC. The paper focuses on the newest updates in epidemiology, symptoms and diagnostic criteria, pathophysiology and highlights some unsolved problems. Moreover, a new treatment algorithm is proposed on the basis of new evidence from well-designed, randomized control trials.

Place, publisher, year, edition, pages
Amsterdam, Netherlands: Elsevier, 2012. Vol. 6, no 9, p. 932-945
National Category
Medical and Health Sciences Gastroenterology and Hepatology
Research subject
Medicine
Identifiers
URN: urn:nbn:se:oru:diva-24222DOI: 10.1016/j.crohns.2012.05.014ISI: 000309990400009PubMedID: 22704658Scopus ID: 2-s2.0-84865736716OAI: oai:DiVA.org:oru-24222DiVA, id: diva2:542844
Funder
AstraZeneca
Note

Funding Agencies:

Tillots Pharma 

Falk Pharma 

Ferring 

Falk Foundation, Germany 

MSD 

MEDA, Sweden 

Note: Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD)

Available from: 2012-08-03 Created: 2012-08-03 Last updated: 2018-05-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Bohr, JohanTysk, Curt

Search in DiVA

By author/editor
Bohr, JohanTysk, Curt
By organisation
School of Health and Medical Sciences, Örebro University, Sweden
In the same journal
Journal of Crohn's & Colitis
Medical and Health SciencesGastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 97 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf